Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Ikena Oncology, Inc.
Ikena Oncology, Inc. News
Jul 25, 2025 - globenewswire.com
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
Jul 23, 2025 - globenewswire.com
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
Ikena Oncology, Inc. Quantitative Score
About Ikena Oncology, Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Ikena Oncology, Inc. Financials
Table Compare
Compare IKNA metrics with: | |||
|---|---|---|---|
Earnings & Growth | IKNA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | IKNA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | IKNA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | IKNA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Ikena Oncology, Inc. Income
Ikena Oncology, Inc. Balance Sheet
Ikena Oncology, Inc. Cash Flow
Ikena Oncology, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Ikena Oncology, Inc. Executives
| Name | Role |
|---|---|
| Dr. Mark Manfredi Ph.D. | President, Chief Executive Officer & Director |
| Dr. Jotin Marango M.D., Ph.D. | Chief Operating Officer, Chief Financial Officer, Head of Corporate Development & Treasurer |
| Mr. David Damphousse M.S. | Senior Vice President of Clinical Development Operations |
| Ms. Rebecca Cohen | Senior Vice President of Investor Relations, Corporate Strategy & Communication |
| Mr. Jeffrey Ecsedy Ph.D. | Chief Development Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Mark Manfredi Ph.D. | President, Chief Executive Officer & Director | 1972 | 868.19K | |
| Dr. Jotin Marango M.D., Ph.D. | Chief Operating Officer, Chief Financial Officer, Head of Corporate Development & Treasurer | 1980 | 809.95K | |
| Mr. David Damphousse M.S. | Senior Vice President of Clinical Development Operations | Male | -- | |
| Ms. Rebecca Cohen | Senior Vice President of Investor Relations, Corporate Strategy & Communication | Female | -- | |
| Mr. Jeffrey Ecsedy Ph.D. | Chief Development Officer | Male | 1970 | -- |
Ikena Oncology, Inc. Insider Trades
| Date | 25 Jul |
| Name | ORBIMED ADVISORS LLC |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 83611 |
| Date | 7 Jun |
| Name | FORMELA JEAN FRANCOIS |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 17520 |
| Date | 7 Jun |
| Name | Bonita David P |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 17520 |
| Date | 7 Jun |
| Name | Wooster Richard |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 17520 |
| Date | 7 Jun |
| Name | Dukes Iain D. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 17520 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 25 Jul | ORBIMED ADVISORS LLC | Director | Acquired | A-Award | 83611 |
| 7 Jun | FORMELA JEAN FRANCOIS | Director | Acquired | A-Award | 17520 |
| 7 Jun | Bonita David P | Director | Acquired | A-Award | 17520 |
| 7 Jun | Wooster Richard | Director | Acquired | A-Award | 17520 |
| 7 Jun | Dukes Iain D. | Director | Acquired | A-Award | 17520 |